Drug Trial Radar · NCT02616146
Efficacy and Safety of Etonogestrel + 17β-Estradiol Vaginal Ring and Levonorgestrel-Ethinyl Estradiol Combined Oral Contraceptive in Adult Women at Risk for Pregnancy (MK-8342B-062)
Last checked: Nov 19, 2026Latest source record: May 17, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
2,016
Actual
Start
Dec 1, 2015
Primary completion
Oct 6, 2016
Study completion Oct 6, 2016
Sponsor
- Lead sponsor
- Organon and CoIndustry
- Sponsor type
- Industry
- First posted
- Nov 26, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the contraceptive efficacy of the etonogestrel + 17β-estradiol (ENG-E2) vaginal ring in women between 18 and 35 years of age based on the number of in-treatment pregnancies as expressed by the Pearl Index (PI). The study will also assess the safety and tolerability of ENG-E2 vaginal ring. The levonorgestrel-ethinyl estradiol (LNG-EE) 150/30 μg combined oral contraceptive (COC) will be used as the active comparator.
Conditions
- Contraception
Interventions
ENG-E2 125 μg/300 μg vaginal ringDrug
Up to 13 cycles of ENG-E2 125 μg/300 μg administered intravaginally, each cycle consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
LNG-EE 150 μg/30 μg COCDrug
Up to 13 cycles of LNG-EE 150 μg/30 μg administered orally, each cycle consisting of one tablet per day for 21 days, followed a 7-day tablet-free interval.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of In-Treatment Pregnancies Per 100 Woman-Years of Exposure in Participants 18-35 Years of Age (Pearl Index)Time frame: Up to 1 year (13 28-day cycles)
- Number of Participants Who Experienced an Adverse Event (AE)Time frame: Up to 1 year
- Number of Participants Who Discontinued Treatment Due to an AETime frame: Up to 1 year
Locations
14 sites in 14 countries. Site status is shown where the registry gives one.
MSD Osterreich GmbH
Vienna, Austria
Merck Sharp & Dohme
San José, Costa Rica
Merck Sharp & Dohme
Glostrup Municipality, Denmark
MSD Finland Oy
Espoo, Finland
Merck Sharp & Dohme GmbH
Haar, Germany
MSD Pharma Hungary Kft.
Budapest, Hungary
MSD Italia S.r.l.
Rome, Italy
MSD
Mexico City, Mexico
Merck Sharp & Dohme BV
Haarlem, Netherlands
MSD Norge A/S
Drammen, Norway
Merck Sharp & Dohme, Peru S.R.L.
Lima, Peru
MSD Polska Sp. Z o.o.
Warsaw, Poland
MSD (Pty) LTD South Africa
Midrand, South Africa
MSD Sweden
Stockholm, Sweden
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.